About NADH-ubiquinone oxidoreductase chain 4
NADH-ubiquinone oxidoreductase chain 4 (MT-ND4) is a protein
from Homo sapiens identified by UniProt accession
P03905, 459 residues long.
MolForge cross-references it against 0 known binders and
375 disease associations.
Target properties
| Protein name | NADH-ubiquinone oxidoreductase chain 4 |
| UniProt accession | P03905 |
| Gene | MT-ND4 |
| Organism | Homo sapiens |
| Length | 459 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (375)
Diseases linked to this target (Open Targets).
- Leber hereditary optic neuropathy · score 0.75
- MELAS syndrome · score 0.73
- MELAS · score 0.69
- mitochondrial disease · score 0.66
- Leber plus disease · score 0.66
- type 2 diabetes mellitus · score 0.61
- mitochondrial complex I deficiency · score 0.61
- diabetes mellitus · score 0.60
- polycystic ovary syndrome · score 0.60
- type 1 diabetes mellitus · score 0.58
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P03905-F1 | alphafold | PREDICTED | 93.94 | — |
Amino-acid sequence (459 residues)
MLKLIVPTIM LLPLTWLSKK HMIWINTTTH SLIISIIPLL FFNQINNNLF SCSPTFSSDP LTTPLLMLTT WLLPLTIMAS QRHLSSEPLS RKKLYLSMLI SLQISLIMTF TATELIMFYI FFETTLIPTL AIITRWGNQP ERLNAGTYFL FYTLVGSLPL LIALIYTHNT LGSLNILLLT LTAQELSNSW ANNLMWLAYT MAFMVKMPLY GLHLWLPKAH VEAPIAGSMV LAAVLLKLGG YGMMRLTLIL NPLTKHMAYP FLVLSLWGMI MTSSICLRQT DLKSLIAYSS ISHMALVVTA ILIQTPWSFT GAVILMIAHG LTSSLLFCLA NSNYERTHSR IMILSQGLQT LLPLMAFWWL LASLANLALP PTINLLGELS VLVTTFSWSN ITLLLTGLNM LVTALYSLYM FTTTQWGSLT HHINNMKPSF TRENTLMFMH LSPILLLSLN PDIITGFSS
Explore NADH-ubiquinone oxidoreductase chain 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets